Kingswood Wealth Advisors LLC Reduces Position in Johnson & Johnson $JNJ

Kingswood Wealth Advisors LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 57.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,760 shares of the company’s stock after selling 17,277 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,949,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. Global Strategic Investment Solutions LLC grew its position in Johnson & Johnson by 3.5% in the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after buying an additional 65 shares during the last quarter. JSF Financial LLC boosted its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after purchasing an additional 65 shares in the last quarter. Elios Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its position in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after purchasing an additional 67 shares in the last quarter. Finally, MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.5%

Shares of JNJ stock opened at $189.75 on Thursday. The firm has a 50-day moving average price of $177.49 and a 200 day moving average price of $163.37. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $190.22. The company has a market capitalization of $456.98 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 2.41 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Citigroup boosted their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. HSBC lifted their price target on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.